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PART I  
DELAYED ISCHAEMIC NEUROLOGICAL DEFICITS (DIND) AFTER 
ANEURYSMAL SUBARACHNOID HAEMORRHAGE  
I 1  
Epidemiology  
 
Although cerebral haemorrhage represents only 10%-15% of all strokes, it has been 
estimated to cause more than 50% of the overall stroke mortality (Bamford et al. 1990). The 
30-day mortality rate at around 45% is similar for intracranial and subarachnoid haemorrhage 
(SAH) (Broderick et al. 1993). SAH represents one quarter to one third of all cerebral 
haemorrhages (Nilsson et al. 2000). The more recent studies have estimated an annual rate of 
SAH between 6 in North America and 10 in Europe per 100,000 population (Broderick et al. 
1993; Nilsson et al. 2000). Women are affected about twice as often compared with men 
(Broderick et al. 1993; Nilsson et al. 2000). Approximately 75% of spontaneous SAHs are 
caused by intracranial aneurysms (Nilsson et al. 2000). 
In a recent population-based European study, 16% of the patients with SAH died 
before reaching the hospital. Another 5% deceased at the day of haemorrhage after admission 
(Pobereskin 2001). Among patients surviving the initial haemorrhage treated without surgery, 
rebleeding is the major cause of morbidity and mortality. The risk is between 15% and 20% 
within the first two weeks. The goal of early surgery is to reduce this risk. Of those reaching 
neurosurgical care, secondary deterioration caused by delayed ischaemic neurological deficits 
(DINDs) is assumed to be the predominant complication after SAH. In the international 
cooperative study on the timing of aneurysm surgery, DINDs were responsible for disability 
in 6.3% and mortality in 7.2% among patients with SAH (Kassell et al. 1990a). The recent 
randomised, double-blind, vehicle-controlled trials of tirilazad mesylate found a rate of 33% 
to 38% for DINDs in all patients of the vehicle group. Cerebral infarctions occurred in 10% to 
13% (Haley et al. 1997; Lanzino and Kassell 1999; Lanzino et al. 1999). 
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I 2  
Clinical presentation 
 
DINDs are clinically characterised by confusion or decreased level of consciousness 
with a focal neurological deficit. The diagnosis is one of exclusion. In contrast to the usual 
clinical presentation of stroke, symptoms typically develop gradually, waxing and waning 
over several hours. Increased headache and meningismus, low-grade fever, seizures, and a 
disturbance of consciousness are usually followed by the appearance of focal neurological 
symptoms that typically reflect ischaemia in the anterior circulation. Characteristic signs 
include mental status changes, abulia, akinesia, anosagnosia, Witzelsucht, aphasia, 
hemiparesis, paraparesis or urinary incontinence (Adams and Love 1992). 
 
I 3  
Risk factors 
 
 It has been hypothesised that intracellular products of red blood cells induce DINDs 
(MacDonald and Weir 1991). This hypothesis has been based on: (a) the temporal correlation 
between the occurrence of DINDs (day 4 - 12 after the haemorrhage, maximum at day 7) and 
haemolysis in the subarachnoid space (Pluta et al. 1998), and (b) the correlation between the 
amount of subarachnoid blood in the initial computed tomogram (CT) and the risk to develop 
a DIND (Fisher et al. 1980; Kistler et al. 1983; Brouwers et al. 1993). Up to 70% of patients 
develop angiographically visible delayed arterial spasm after SAH (Brouwers et al. 1993). 
While the absence of angiographic spasm has a high negative predictive value, the positive 
predictive value of moderate/severe angiographic spasm for the development of a DIND is 
only between 33% and 50% (Vora et al. 1999; Unterberg et al. 2001). This positive predictive 
value is less than that of a coin toss suggesting additional pathogenetic factors.  
Most “classical” vascular risk factors seem to increase the likelihood for a DIND. 
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Thus, in cigarette smokers, a slightly higher risk for the development of DINDs has been 
observed. Weir et al. (1998) analysed 3500 patients from five multi-centre trials and found an 
odds ratio of 1.2 (95% confidence interval 1.1-1.4). A higher prevalence of hypertension in 
patients developing a DIND was suggested in case-control studies (Brandt et al. 1991; Öhman 
et al. 1991). Even though age was negatively correlated with angiographic spasm, the 
incidence of DINDs was either similar to that observed in younger patients (Fortuny et al. 
1980) or increased with advancing age (Lanzino et al. 1996). This is possibly related to the 
finding that the subarachnoid clot is thicker in elderly patients due to parenchymal atrophy 
allowing for a larger quantity of blood to collect (Inagawa et al. 1988; Sakaki et al. 1989). In 
addition, the prevalence of hypertension is higher in the elderly. As another risk factor for the 
evolution of a DIND, cocaine use was identified (Conway and Tamargo et al. 2001). To my 
knowledge, a particular study related to diabetes and DIND has not been performed, yet. A 
causal link between hyperglycaemia and outcome after DIND was not established in the 
Cooperative Aneurysm Study (Lanzino et al. 1993).  
Only the gender relation for DINDs is clearly different from that of most other 
variants of ischaemic stroke, which show a significant male preponderance. In contrast, the 
incidence of DINDs was either similar in men and women with SAH (North American Study) 
(Kongable et al. 1996) or significantly higher in women (European Studies) (George et al. 
1989; Rosenorn et al. 1993). DINDs share this epidemiological feature with migraine-related 
stroke (Tzourio et al. 2000). However, although migraine, particularly migraine with aura, has 
been established as a risk factor for ischaemic stroke in all recent population- and hospital-
based studies (reviewed by Tzourio et al. 2000), it has not been investigated so far whether 
the coexistence of migraine is linked to an increased risk for DINDs. To my knowledge, there 
are also no epidemiological studies regarding female hormones and incidence of DINDs.   
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I 4  
Differential diagnosis 
I 4.1  
Re-bleeding 
 
Maximal frequency of re-bleeding after aneurysmal SAH is in the first day (4% on the 
first day, then 1.5% daily for 13 days). Fifteen to 20% re-bleed within the first two weeks 
(Winn et al. 1977). The risk was neither altered by blood pressure on admission nor site of the 
aneurysm (Inagawa et al. 1987). Early surgery prevents re-bleeding.  
 
I 4.2  
Hydrocephalus 
 
Acute hydrocephalus was observed on admission CT in 15% of SAH patients with 
40% of these being symptomatic (Graff-Radford et al. 1989). Factors assumed to contribute to 
acute hydrocephalus include: blood interfering with cerebrospinal fluid circulation through 
the Sylvian aqueduct, fourth ventricle outlet, subarachnoid space, and/or with re-absorption at 
the arachnoid granulations. Chronic hydrocephalus is due to pia-arachnoid adhesions or 
permanent impairment of the arachnoid granulations. Acute hydrocephalus does not 
inevitably lead to chronic hydrocephalus. Cerebral lesions typically associated with 
hydrocephalus are located at the ventricle poles.   
 
I 4.3  
Hyponatraemia 
 
Hyponatraemia commonly occurs following SAH. Although it had been attributed to a 
rise in antidiuretic hormone (ADH) producing hypervolaemic hyponatraemia, the ADH 
increment is usually transient, lasting for only about 4 days. Another theory was based on the 
fact that there is often a delayed peak in atrial natriuretic factor (ANF), a 28-amino acid 
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polypeptide, after an initial smaller rise (Wijdicks et al. 1991). Increased ANF secretion leads 
to a urinary loss of sodium (cerebral salt wasting syndrome) resulting in hypovolaemic 
hyponatraemia. Although cerebral salt wasting syndrome has clearly been shown to be the 
cause of hyponatraemia in the majority of these patients (Harrigan 1996), it has remained 
unclear whether ANF is the operative natriuretic factor in SAH (Kröll et al. 1992). The 
neurological effects of hyponatraemia can mimic DINDs. 
 
I 4.4  
Peri- and intra-operative complications associated with aneurysm clipping 
 
A particular problem in studying DINDs is the differentiation from peri- or intra-
operative complications associated with aneurysm clipping. Direct or indirect surgical 
complications have a different pathogenesis from DINDs and, hence, are likely to be different 
in pathoanatomy of the cerebral lesions, age and gender distribution, risk factor profile and 
response to medical treatment. In other words, surgically related ischaemic infarcts represent 
an important confounding factor in studies on DINDs. Unfortunately, in many studies on 
DINDs, surgical complications were not adequately controlled. E.g., Millikan, in 1975, 
expatiated upon his experience from a series of 198 patients that “any diffuse or focal brain 
damage, which occurs after the first few hours following the bleed or particularly following a 
neurosurgical procedure, is automatically explained as being due to vasospasm”. This clinical 
problem is further complicated by the interaction between delayed vasospasm with 
parenchyma partially damaged during the surgical procedure since partial damage may result 
in increased vulnerability. That interaction might also result in delayed neurological deficits 
although the pathogenesis would be different from that of DINDs in non-operated patients. 
Serial magnetic resonance imaging (MRI) could help to differentiate between surgically 
related and unrelated lesions when images taken at the second post-operative day are 
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compared with those at, e.g., day 12 after the haemorrhage. Unfortunately, the serial MRI 
study of Shimoda et al. (2001) is inconclusive in this respect. Concerning aneurysm closure 
and its ischaemic consequences in MR images, the recent, comparative study of aneurysm 
coiling or clipping by Hohlrieder et al. (2002) is interesting. Of the 112 patients treated after 
aneurysm rupture, 57% suffered from ischaemic infarcts. However, also the 32 patients in 
whom the aneurysm was electively coiled or clipped showed secondary cerebral infarcts in 
41%. 
Direct intra-operative complications resulting in ischaemia are, e.g., spatula pressure, 
stenosis of the aneurysm-bearing vessel by the surgical clip around the aneurysm neck, 
generalised brain swelling or aneurysm rupture. The most important surgical complication is 
probably thrombosis occurring post-operatively and requiring post-operative control 
angiography to be distinguished from a DIND. E.g., Proust et al. (1995) investigated 230 
consecutive patients with ruptured aneurysm. Whereas post-operative thrombosis occurred in 
25 cases (11%), DINDs caused only 15 secondary complications in this study (7%). Similar 
percentages for post-operative thrombosis were reported in other studies with systematic 
control angiography (11% in a series of 100 subjects [Creissard et al. 1990], 12% in a series 
of 66 subjects [MacDonald et al. 1993] and 11% of 63 patients who died after aneurysm 
surgery [Karhunen et al. 1991]), whereas the incidence was considerably lower in studies 
without systematic control angiography (3% in the International Cooperative Study on 
Aneurysm Surgery [3521 patients, Kassell et al. 1990b] and 4% in a series of 150 patients 
[Gilsbach et al. 1988]). That comparison suggests that post-operative thrombosis is the most 
important confounding factor for DINDs in studies without systematic control angiography.   
In summary, the differentiation between DINDs and surgically related ischaemic 
infarcts is difficult and controversial. Only for ischaemic lesions in the cortex associated with 
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DINDs, it was shown that surgery was not a confounding factor (Neil-Dwyer et al. 1994). 
Most surgically related complications including post-operative thrombosis will produce 
territorial infarcts. 
 
I 4.5  
Ischaemic stroke unrelated to surgical complications or DIND in the post-operative 
course 
 
The incidence of different variants of ischaemic stroke is significantly increased for 
any kind of surgery during the post-operative period from the hospitalisation until 30 days 
after surgery. This may be related to changes in coagulation, bed rest, medication, diagnostic 
tests etc. (Wong et al. 2000). In addition, it is likely that the rate of stroke caused by cardiac 
embolism is particularly increased after SAH since SAH is well known to produce cardiac 
arrhythmias (reviewed by Sakr et al. 2002). However, the role of cardiac embolism, 
atherosclerosis or other frequent aetiologies of ischaemia for ischaemic deficits after SAH has 
never been adequately studied to my knowledge. These aetiologies may particularly 
contribute to ischaemic complications after SAH in the elderly. The majority of these 
aetiologies, in particular cardiac embolism, will produce territorial infarcts.  
 
I 5  
Pathoanatomy 
 
Robertson performed the first pathoanatomical study on DINDs in 1949. A 
microscopically detected infarct of motor cortex in case number 8 of the original publication 
laid the foundation of the hypothesis that ischaemic changes can occur remote from the 
territory of the artery bearing the aneurysm. From a large autopsy series, Falconer reported 
similar findings in 1954. As a typical example, he presented a case of a non-operated patient 
with a left anterior cerebral artery aneurysm in whom a cortical necrosis was detected in the 
territory of the left middle cerebral artery. Birse and Tom, in 1960, presented a detailed 
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histological analysis of these widespread ischaemic lesions after SAH in 8 selected autopsy 
cases of non-operated patients. They provided clear diagrams emphasizing the characteristic 
focal cortical distribution of the infarcts, which were often arranged around a fissure or a 
sulcus (Fig. 1A and B). Deeper structures of the brain showed small ischaemic patches. 
Stoltenburg-Didinger and Schwarz published a large autopsy study of operated and non-
operated patients in 1987. They analysed 207 cases after aneurysmal SAH collected from 
1969 to 1985. In 106 of 139 patients properly examined microscopically, either bell-shaped or 
laminar infarcts in the cortex were a constant finding. The large majority of these cortical 
infarcts occurred in areas covered with a subarachnoid clot. Of the 156 patients not 
undergoing surgery, only 9 demonstrated a larger infarct in the territory of one of the three 
major cerebral arteries (6%). In contrast, 13 of the 51 patients in whom a clipping of the 
ruptured aneurysm was performed, showed a territorial infarct (26%) (Chi-Square-
Independence-test, p < 0.0001). This indicated some pathogenetic role of the surgical 
intervention for a considerable number of territorial infarcts. Neil-Dwyer and colleagues, in 
1994, performed a prospective autopsy study including 53 cases. This study aimed to 
differentiate between the lesions induced by the initial haemorrhage and that by delayed 
ischaemia. A significant correlation was confirmed between delayed ischaemia and cortical 
ischaemic lesions. Interestingly, moderate to severe cortical ischaemic lesions were also 
detected in 56% of patients without evidence of vasospasm in the angiogram. 
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 Figure 1 
A and B 
The upper two pictures 
are diagrammatic 
representations of 
macroscopic and 
microscopic cerebral 
infarction in a 37-year old 
man with DIND at day 8 
after subarachnoid 
haemorrhage. The DIND 
was characterised by a 
rapid deterioration with 
development of 
paraplegia. The patient 
died 4 days later. The 
pictures are taken from a 
paper of 8 cases selected 
from a larger autosy 
series by Sheila Birse and 
Mary Tom published in 
Neurology in 1960.  
The lower two pictures 
are turbo inversion 
recovery magnitude 
magnetic resonance 
images from a 33-year old 
man who developed a 
DIND with mental status 
changes and right-sided 
hemiparesis about 6 days 
after subarachnoid 
haemorrhage (Dreier et 
al. 2002b). The patient 
was treated in the 
intensive care unit with a 
good recovery. In both 
patients, the aneurysm 
was un-operated at the 
time point when the 
pictures were made so 
that the lesions represent 
the typical pattern 
occurring in the natural 
course of the disease. The 
most characteristic 
feature of the lesions is 
their distribution in the 
cortex band around a 
sulcus (arrows in A) or a 
fissure (arrows in B). In 
both patients, the 
aneurysm was located at 
the anterior 
communicating artery in which case the blood is typically pushed upwards along the interhemispheric fissure.  
C A similar focal laminar cortical necrosis is observed after cortical spreading ischaemia in response to the red 
blood cell products haemoglobin and increased subarachnoid K+ in the rat (*). The bar illustrates size and 
position of the cranial window. It is unclear why the lesion can extend beyond the borders of the window. Likely, 
haemoglobin and K+ have diffused to areas neighbouring the window (Dreier et al. 2000). 
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I 6  
Treatment  
I 6.1  
Relative risk reduction of poor outcome after SAH by nimodipine 
 
A recent systematic review of all randomised controlled clinical trials on Ca2+-
antagonists in patients with SAH (2756 patients in total) confirmed a significant reduction in 
frequency of poor outcome by nimodipine. This resulted from a reduction in the occurrence of 
DINDs (Feigin et al. 1998). Nimodipine prevents 1 of 3 bad outcomes due to a DIND. One of 
7 patients develops a bad outcome due to a DIND after SAH (Kassell et al. 1990a). Hence, 
about 21 patients have to be treated with nimodipine to prevent one bad outcome after SAH. 
This beneficial effect was shown for oral nimodipine. It is unclear why the more expensive 
intravenous nimodipine is routinely used in many centers. 
At the cellular level, nimodipine directly inhibits slowly inactivating voltage-sensitive 
Ca2+ channels (L-type). Blockade of Ca2+ entry from the extracellular space into vascular 
smooth muscle leads to cerebral vasodilatation and increases cerebral perfusion (Kazda and 
Towart 1982; Andersson et al. 1983; Haws et al. 1983). It was proposed that Ca2+ antagonists 
may reverse chronic vasospasm of the major cerebral arteries (Allen and Bahr 1979). 
However, no significant effect on cerebral vasospasm was angiographically detected 
following nimodipine treatment in several randomised clinical trials (Feigin et al. 1998). In 
addition, chronic vasospasm induced by autologous blood in the subarachnoid space did not 
resolve in response to high doses of nimodipine in primates (Espinosa et al. 1984; Nosko et al. 
1985; Lewis et al. 1988). Haemoglobin is assumed to play a major role in the pathogenesis of 
the large artery spasm (MacDonald and Weir 1991; Pluta et al. 1998). However, nimodipine 
poorly antagonised haemoglobin-induced arterial constriction in different species such as 
monkey, dog and man (Nosko et al. 1986).  
These clinical and experimental findings suggested that the anti-ischaemic effect of 
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nimodipine may be related to a direct protection of neurons through blockade of excitotoxic 
Ca2+ entry (Brandt et al. 1988; Pisani et al. 1998). However, if a cytoprotective effect on 
neurons was the key function of nimodipine, the drug would also act on other types of 
ischaemia than DINDs. In several animal studies of focal cerebral ischaemia, nimodipine was 
not consistently effective (Langley and Sorkin 1989; Scriabine et al. 1989). In a recent meta-
analysis, no evidence was available to justify the use of nimodipine in patients with ischaemic 
stroke unrelated to SAH (Horn and Limburg 2001).  
 
I 6.2  
Systemic blood volume and DINDs 
 
The risk reduction over the last 20 years to develop delayed ischaemia has not only 
been related to the prophylactic use of nimodipine but also to an improved fluid management. 
In approximately one-third of the patients after SAH, excessive natriuresis and intravascular 
volume contraction occurs (van Gijn and Rinkel 2001). In the past, hyponatraemia was 
erroneously attributed to water retention. Therefore, fluid restriction was applied which was 
later found to increase the risk for DIND. Two non-randomised studies with historical 
controls suggested that a daily fluid intake > 3 l of saline (against 1.5 – 2 l in the past) was 
associated with a lower rate of DINDs (Hasan et al. 1989; Vermeij et al. 1998). In addition, a 
randomised study was performed comparing controls and patients treated with volume 
expansion using albumin and crystalloid to obtain a haematocrit of 45% (Rosenwasser et al. 
1983). In this small trial, moderate hypervolaemic haemodilution resulted in a significant 
reduction of DINDs. A more intense prophylactic volume expansion with elevated cardiac 
filling pressures was not superior to a moderate volume expansion (Lennihan et al. 2000; 
Egge et al. 2001). Hyponatraemia per se does not increase the risk of a DIND (Qureshi et al. 
2002). 
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In patients with ischaemic stroke unrelated to SAH, haematocrit levels were 
significantly higher than in matched controls (Toghi et al. 1978; Harrison et al. 1981). 
However, in contrast to the benefit of patients with DIND, a meta-analysis did not find any 
evidence that moderate volume expansion improved outcome (Asplund et al. 2001). 
 
I 7  
Animal models 
 
Megyesi et al. (2000) counted 57 different SAH models in animals to study the arterial 
spasm. All known models share the feature that DINDs or ischaemic lesions are essentially 
never observed despite the presence of significant arterial spasm (Megyesi et al. 2000). This, 
once again, suggests that the arterial spasm alone is probably not sufficient to induce DINDs. 
That DINDs do not occur in animal SAH models in contrast to SAH in man may be due to the 
better collateralisation in smaller mammals. However, the main reason is probably related to 
the clinical observation that the amount of blood in fissures and cisterns in the initial CT after 
SAH is well correlated with the incidence of DINDs (Fisher et al. 1980; Kistler et al. 1983; 
Brouwers et al. 1993). This suggests that a considerable quantity of blood has to collect to 
induce a DIND. It is obvious that the subarachnoid space of man can accommodate a 
significantly larger volume of blood than that of the species used for SAH models (rat, rabbit, 
cat, pig, dog, smaller primates). The observation by Stoltenburg-Didinger and Schwarz (1987) 
that the lesions typically occurred in areas covered with subarachnoid clot indicated a direct 
effect of the red blood cell products on the underlying cortex in addition to inducing arterial 
spasm at the base of the brain. A possibility to circumvent the problem of the limited 
subarachnoid space in the rat and to model the accumulation of red blood cell products at the 
cortical surface is to directly superfuse these products. With aid of this approach, we have 
demonstrated that red blood cell products are indeed able to produce ischaemia and ischaemic 
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cortical lesions (Fig. 1C) (Dreier et al. 1998; 2000). Relevance of this model for the clinical 
condition was supported by the therapeutic effect of nimodipine and increase of the systemic 
volume, respectively (Dreier et al. 2002a).  
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PART II  
SUMMARY OF OUR OWN RESULTS 
II 1  
Dreier JP, Körner K, Görner A, Lindauer U, Weih M, Villringer A, Dirnagl U. Nitric 
oxide modulates the CBF response to increased extracellular potassium. J Cereb Blood 
Flow Metab. 1995 15:914-919. 
 
The response of the regional cerebral blood flow (CBF) to brain topical superfusion of 
an increased K+ concentration in the artificial cerebrospinal fluid (ACSF) ([K+]ACSF) at 20 
mM was characterised in a closed cranial window preparation in barbiturate anaesthetised and 
ventilated rats. It was concluded that the vasodilator nitric oxide (NO) is a modulator of the 
rise in CBF following increased [K+]ACSF. 
As a by-product of this study, we accidentally discovered spontaneous ischaemic 
responses of an unknown mechanism in response to the co-application of an inhibitor of the 
NO-synthase (NOS) with increased [K+]ACSF. These spontaneous ischaemic responses were 
characterised in the next study. 
 
II 2  
Dreier JP, Körner K, Ebert N, Görner A, Rubin I, Back T, Lindauer U, Wolf T, 
Villringer A, Einhäupl KM, Lauritzen M, Dirnagl U. Nitric oxide scavenging by 
hemoglobin or nitric oxide synthase inhibition by N-nitro-L-arginine induces cortical 
spreading ischemia when K+ is increased in the subarachnoid space. J Cereb Blood Flow 
Metab. 1998 18:978-990. 
 
 It turned out that the spontaneous ischaemic responses to the co-application of a NOS 
inhibitor with increased [K+]ACSF were caused by an inverted coupling between 
neuronal/astroglial metabolism and CBF: The increased [K+]ACSF triggered a 
neuronal/astroglial depolarisation wave which, under physiological conditions, leads to a 
cortical spreading hyperaemia. However, under the conditon of NOS inhibitor with increased 
[K+]ACSF, the coupling was inverted so that vasoconstriction was induced instead of 
vasodilatation resulting in energy compromise. Under this condition, the neuronal/astroglial 
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network was unable to repolarise since the process of repolarisation requires energy. Because 
the vasoconstrictive stimulus was coupled to the neuronal/astroglial depolarisation, a vicious 
circle of prolonged ischaemia was established. That neuronal activation can induce ischaemia, 
was an unexpected finding. The most characteristic feature of this new ischaemic variant was 
its propagation in the cerebral cortex together with the neuronal/astroglial depolarisation 
wave. This caused us to name it ‘cortical spreading ischaemia’. 
 The most potent natural NO-lowering agent is haemoglobin when it is released into 
the extracellular space. Haemoglobin binds NO with an affinity 1500 times higher than its 
affinity for oxygen at its haeme iron and reactive sulfhydril groups at cysteineβ93. Therefore, 
we investigated whether cortical spreading ischaemia also occurred in response to 
haemoglobin and increased [K+]ACSF. We showed that this protocol was at least similarly 
effective as NOS inhibition with increased [K+]ACSF (Fig. 2). 
Haemoglobin (21.03 ± 0.75 mM) and K+ (102.4 ± 3.9 mM) are the protein and ion, 
respectively, with the highest concentration in the red blood cell. As described in PART I, 
DINDs occur in a close temporal correlation with haemolysis of the subarachnoid blood. The 
subarachnoid level of haemoglobin reaches its maximum on the seventh day after SAH (Pluta 
et al. 1998). Values of up to 500 µM have been reported from intracranial haematomas in 
humans (Ohta et al. 1980). Similarly, extracellular K+ concentrations of up to 50 mM were 
measured in intracranial haematomas in neurosurgical patients (Ohta et al. 1983). This led to 
the hypothesis that DINDs may be caused by a mechanism related to cortical spreading 
ischaemia. 
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Figure 2 
Under physiological conditions, a cortical spreading hyperaemia (upper trace, left part) (CBF = cerebral blood 
flow) is coupled to a spreading neuronal depolarisation wave (lower trace, left part) (DC = slow direct current 
potential) propagating from cranial window 1 to cranial window 2. However, when red blood cell products, 
haemoglobin and increased K+, are in the subarachnoid space, the coupling between neuronal activation and 
cerebral blood flow is inverted so that a cortical spreading ischaemia (upper trace, right part) is coupled to the 
spreading neuronal depolarisation wave (lower trace, right part). Due to a vicious circle, both depolarisation 
wave and its CBF response are prolonged under this condition (see text). 
 
 
 
II 3 
Dreier JP, Ebert N, Priller J, Megow D, Lindauer U, Klee R, Reuter U, Imai Y, 
Einhäupl KM, Victorov I, Dirnagl U. Products of hemolysis in the subarachnoid space 
inducing spreading ischemia in the cortex and focal necrosis in rats: a model for delayed 
ischemic neurological deficits after subarachnoid hemorrhage? J Neurosurg. 2000 
93:658-666. 
 
 In this study, we showed that cortical spreading ischaemia induced by haemoglobin 
and increased [K+]ACSF in the rat led to bell-shaped or laminar infarcts in the cortex very 
similar to the pathoanatomical pattern of DINDs in man (Fig. 1). That the lesions are 
essentially restricted to the brain cortex is explained by the fact that spreading neuronal 
depolarisation waves do not run in the white matter. Deeper structures may only be damaged 
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by the waves when long penetrating arteries are constricted at the cortical level. 
 
II 4 
Dreier JP, Petzold G, Tille K, Lindauer U, Arnold G, Heinemann U, Einhäupl KM, 
Dirnagl U. Ischaemia triggered by spreading neuronal activation is inhibited by 
vasodilators in rats. J Physiol (Lond). 2001 531(Pt 2):515-526.  
 
In this study, we investigated the effect of an NO-dependent and NO-independent 
vasodilator, S-nitroso-N-acetylpenicillamine and papaverine, respectively, on cortical 
spreading ischaemia produced by NOS inhibition with increased [K+]ACSF. We found that 
particularly the NO-donor but also papaverine was able to convert cortical spreading 
ischaemia to cortical spreading hyperaemia.  
 
II 5 
Dreier JP, Sakowitz OW, Unterberg AW, Benndorf G, Einhäupl KM, Valdueza JM. 
Migrainous aura starting several minutes after the onset of subarachnoid hemorrhage. 
Neurology. 2001 57:1344-1345.  
 
The Brazilian physiologist Leão first described neuronal/astroglial depolarisation 
waves. He coined the name ‘cortical spreading depression’ in 1944. One year later, together 
with his colleague Morison, he came up with the hypothesis that cortical spreading depression 
may be the correlate of migrainous aura based on the striking resemblance of its 
electrophysiological features and the clinical presentation of migrainous aura. Cortical 
spreading depression is a short, regenerative depression of spontaneous neuronal activity in 
the grey matter that propagates at a rate of approximately 3 mm/min (Lauritzen 1994). The 
neuronal/astroglial depolarisation wave underlying cortical spreading ischaemia is not the 
same as but closely related to cortical spreading depression. Therefore, it was obvious to 
investigate whether migrainous aura-like symptoms may occur during the clinical course after 
SAH. Interestingly, within a short period of time, we found two patients with migraine who 
   
  18  
 
 
 
 
experienced migrainous-aura like symptoms several minutes after the onset of acute headache 
induced by SAH. Both patients developed a DIND later on. Unfortunately, at the time of 
DIND, the patients were unable to adequately describe their symptoms because of a 
profoundly altered mental status. However, also the initially gained information on a 
migrainous aura-like attack as a symptom of SAH was remarkable since literature suggests 
the occurrence of spreading depression-like depolarisations at the acute stage of SAH in 
animal models (Hubschmann and Kornhauser 1980; Busch et al. 1998). Our findings were 
also of clinical value since migraine is the most important misdiagnosis of SAH, which can 
lead to a delay of aneurysm surgery (Edlow and Caplan 2000). 
 
II 6 
Dreier JP, Kleeberg J, Petzold G, Priller J, Windmuller O, Orzechowski HD, Lindauer 
U, Heinemann U, Einhaupl KM, Dirnagl U. Endothelin-1 potently induces Leao's 
cortical spreading depression in vivo in the rat: a model for an endothelial trigger of 
migrainous aura? Brain. 2002 125:102-112. 
 
The 21-residue peptide endothelin-1 has gained much attention in neurological and 
neurosurgical research being both a powerful vasoconstrictor and a neuronal and astroglial 
modulator. Numerous studies have investigated whether endothelin-1 is involved in the 
pathogenesis of arterial spasm after SAH (reviewed by Zimmermann and Seifert 1998). 
Endothelin-1 was also suggested to play a role in stroke and migraine. In our animal study, we 
demonstrated that this endothelium-derived factor is the most potent inductor of cortical 
spreading depression currently known. This may have implications particularly for migraine 
research since clinical observations strongly suggest that endothelial irritation may somehow 
initiate one of the pathways leading to cortical spreading depression. In addition, it may be of 
significance for DINDs since preliminary results indicate that endothelin-1 can replace 
increased [K+]ACSF in the protocol used to initiate cortical spreading ischaemia.  
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II 7 
Dreier JP, Windmüller O, Petzold G, Lindauer U, Einhäupl KM, Dirnagl U. Ischemia 
triggered by red blood cell products in the subarachnoid space is inhibited by 
nimodipine administration or moderate volume expansion/hemodilution in rats. 
Neurosurgery. 2002 51:1457-1467. 
 
Over the last 20 years, the risk to develop a DIND has significantly decreased. This 
has been related, at least partially, to the prophylactic use of nimodipine and improved fluid 
management (see above). In this study, we investigated whether nimodipine or moderate 
hypervolaemic haemodilution convert cortical spreading ischaemia produced by haemoglobin 
with increased [K+]ACSF to cortical spreading hyperaemia (compare II 4). The positive result 
of our study supported a link between DINDs and cortical spreading ischaemia (Fig. 3).  
 
II 8 
Dreier JP, Sakowitz OW, Harder A, Zimmer C, Dirnagl U, Valdueza JM, Unterberg 
AW. Focal laminar cortical MR-signal abnormalities after subarachnoid hemorrhage. 
Ann Neurol. 2002 52:825-829. 
 
It is often erroneously believed that the typical substrate of DINDs after SAH are 
territorial infarcts. This is not supported by the autopsy studies, which showed a large 
predominance of triangular, round or laminar cortical ischaemic lesions and, in addition, 
ischaemic patches in deeper cerebral structures (Robertson 1949; Falconer 1954; Birse and 
Tom 1960; Crompton 1964; Stoltenburg-Didinger and Schwarz 1987; Neil-Dwyer et al. 
1994). In non-operated patients, the relation between autopsy cases with cortical to those with 
territorial infarcts was 13:1, while in operated patients, it was 3:1 due to a relative increase in 
the frequency of territorial infarcts (Stoltenburg-Didinger and Schwarz 1987). The 
significance of the cortical lesions is clinically underestimated because they are typically 
undetected by CT (Stoltenburg-Didinger and Schwarz 1987; Neil-Dwyer et al. 1994). We 
presented two cases demonstrating the suitability of magnetic resonance (MR) imaging to 
visualize such cortical lesions (Fig. 1). 
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Figure 3 
Comparison of cerebral blood flow (CBF)- and direct current (DC)-responses to the spreading 
neuronal/astroglial depolarisation wave (SND). While the upper two traces represent CBF at two different laser-
Doppler positions, the lower trace gives the DC-potential at one cranial window.  
A Physiological artificial cerebrospinal fluid (ACSF) topically, 0.9% saline intravenously (control): The 
depolarisation wave is associated with a cortical spreading hyperaemia (CSH) under physiological conditions 
(= cortical spreading depression (CSD) of Leão).  
B ACSF containing haemoglobin ([Hb]ACSF) and elevated K+ ([K+]ACSF) topically, 0.9% saline intravenously: 
Cortical spreading ischaemia (CSI) in response to the depolarisation wave.  
C ACSF containing the red blood cell products topically, nimodipine is given intravenously at a dose of 2 µg/kg 
bodyweight/min (i.v.): Cortical spreading ischaemia reverts to a cortical spreading hyperaemia in presence of 
nimodipine. Only a short initial hypoperfusion (*) preceding cortical spreading hyperaemia indicates the 
presence of the red blood cell products in the subarachnoid space. The effect of moderate hypervolaemic 
haemodilution was similar to that of nimodipine. 
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PART III  
ASSESSMENT 
 
The occurrence of DINDs was first described five decades ago by Robertson (1949). 
This year of discovery fell into the era of cerebral angiography, which had been introduced by 
Moniz in 1927. When Ecker and Riemenschneider (1951) first demonstrated delayed arterial 
spasm after subarachnoid hemorrhage with cerebral angiography, it was believed that, in 
principal, the pathogenesis of delayed ischaemic neurological deficits was explained, i.e., 
arterial spasm of the Circle of Willis arteries causing cerebral infarction. Today, the key 
words “vasospasm subarachnoid hemorrhage” yield more than 2000 references in the 
medline. However, several findings have challenged the simplistic link between DINDs and 
vasospasm: (a) The clinical match between cerebral angiography findings and DINDs is low 
as briefly reviewed in the present paper. (b) Neil-Dwyer et al. (1994), in their prospective 
autoptic study, not even detected a significant difference regarding the occurrence of DIND-
induced lesions between patients with and without angiographically demonstrated vasospasm. 
(c) Also, the pathoanatomical pattern, the widespread distribution of DIND-induced lesions in 
the cortex, suggests that the key pathophysiological problem is not related to the proximal 
segments of the cerebral arteries. (d) Animal studies of subarachnoid haemorrhage essentially 
failed to demonstrate DINDs or delayed lesions despite angiographically demonstrated 
arterial spasm.  
As an alternative, we have proposed that direct action of RBC products on the 
microcirculation and neuronal/astroglial network may be responsible for the cortical lesions 
associated with DINDs. However, there are also limitations of our approach. The main 
limitation is related to the high concentrations of haemoglobin and [K+]ACSF used for the 
induction of cortical spreading ischaemia. The haemoglobin concentration applied in our 
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experiments was five times higher than that measured in human cerebral haematomas. The 
necessity of relatively high haemoglobin concentrations is possibly due to: (a) The higher 
ischaemic threshold and better collateralisation in small mammals compared with man. An 
influence of the species is supported by the fact that DINDs are not observed in animal SAH 
models (Megyesi et al. 2000). (b) The incubation time with haemoglobin is shorter in our 
experiments compared with that after SAH. (c) The site of haemoglobin application spares the 
base of the brain, so that spasm of basal arteries would not contribute to the energy 
compromise. However, in future studies, it will be interesting to investigate whether lower 
haemoglobin concentrations are sufficient for the induction of cortical spreading ischaemia if 
NO producing sources are disturbed in a similar way as it is probably the case after SAH 
(Pluta et al. 1996).  
The level of [K+]ACSF was also relatively high in our studies. Extracellular K+-levels of 
this magnitude were in fact measured in human cerebral haematomas (Ohta et al. 1983). 
However, the effect of the rise in baseline [K+]ACSF is probably mediated by a gradual rise in 
extracellular K+ in the cortex ([K+]o), a concomitant down-regulation of the (Na+)-(K+)-
ATPase activity and disturbance of the neuronal/astroglial repolarisation (Dreier et al. 2001). 
All these changes can probably also be achieved by other factors than elevated [K+]ACSF, 
which have been implicated in the pathogenesis of DINDs such as energy compromise (due to 
the arterial spasm) (Jamme et al. 1997; Nedergaard et al. 1993; Müller and Somjen 2000), a 
decline in intracerebral glucose concentration (Dreier et al. 2000; Unterberg et al. 2001), or a 
rise in endogenous ouabain-like factors (Dreier et al. 1997; Lusic et al. 1999).  
Our results call for future studies analysing whether spreading depression-like 
depolarisations occur in patients after SAH using monitoring tools like DC-EEG, near-
infrared spectroscopy, microdialysis or functional MRI. In addition, it will be necessary to 
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investigate whether the coupling between neuronal metabolism and CBF is fundamentally 
altered after experimental SAH in animals.   
 
CONCLUSION  
 
The coupling between neuronal activity and cerebral blood flow is a fundamental 
process, which underpins all cerebral functions. The topic of my Habilitation is the discovery 
of a new variant of ischaemia in which neuronal activation triggers a cerebral ischaemic event 
through the inversion of the coupling between neuronal activation and cerebral blood flow. 
This inversion occurs when red blood cell products are present in the subarachnoid space. The 
most distinct feature of this variant of ischaemia is its propagation in the cerebral cortex 
together with the wave of neuronal activation. Therefore, we named the phenomenon ‘cortical 
spreading ischaemia’.  
The presented animal model may have implications for the delayed ischaemic 
neurological deficits after subarachnoid haemorrhage. The link with this clinical syndrome 
has been based: (a) on the induction of cortical spreading ischaemia by red blood cell products 
in the subarachnoid space, (b) the correspondence between the characteristic patterns of the 
cortical ischaemic lesions, (c) and the therapeutic effects of nimodipine and moderate 
hypervolaemic haemodilution in clinical syndrome and animal model. With the aid of this 
model, it was possible to experimentally confirm the hypothesis that red blood cell products 
can induce cerebral ischaemia. We hope that the model will contribute to develop new 
strategies for the treatment of patients with subarachnoid haemorrhage. 
   
  24  
 
 
 
 
References  
Adams HP, Love BB. Medical management of aneurismal subarachnoid hemorrhage. In: 
Barnett HJM, Mohr JP, Stein BM, Yatsu FM (eds). Stroke. Pathophysiology, diagnosis, and 
management. New York, Churchill Livingstone, 1992, pp 1029-1054. 
 
Allen GS, Bahr AL. Cerebral arterial spasm: Part 10. Reversal of acute and chronic spasm in 
dogs with orally administered nifedipine. Neurosurgery 1979 4:43-47. 
 
Andersson KE, Edvinsson L, MacKenzie ET, Skarby T, Young AR. Influence of extracellular 
calcium and calcium antagonists on contractions induced by potassium and prostaglandin F2 
alpha in isolated cerebral and mesenteric arteries of the cat. Br J Pharmacol 1983 79:135-140. 
 
Asplund K, Israelsson K, Schampi I. Haemodilution for acute ischaemic stroke. Cochrane 
Review, Issue 4. 2001. 
 
Bamford J, Sandercock P, Dennis M, Burn J, Warlow C. A prospective study of acute 
cerebrovascular disease in the community: the Oxfordshire Community Stroke Project--1981-
86. 2. Incidence, case fatality rates and overall outcome at one year of cerebral infarction, 
primary intracerebral and subarachnoid haemorrhage. J Neurol Neurosurg Psychiatry. 1990 
53:16-22. 
 
Birse SH, Tom MI: Incidence of cerebral infarction associated with ruptured intracranial 
aneurysms. A study of 8 unoperated cases of anterior cerebral aneurysm. Neurology 1960 
10:101-106. 
 
Brandt L, Andersson KE, Ljunggren B, Saveland H, Ryman T. Cerebrovascular and cerebral 
effects of nimodipine--an update. Acta Neurochir Suppl (Wien) 1988 45:11-20. 
 
Brandt L, Saveland H, Romner B, Ryman T. Does nimodipine eliminate arterial hypertension 
as a prognostic risk factor in subarachnoid haemorrhage? Br J Neurosurg. 1991 5:485-489. 
 
Broderick JP, Brott T, Tomsick T, Miller R, Huster G.  Intracerebral hemorrhage more than 
twice as common as subarachnoid hemorrhage. J Neurosurg. 1993 78:188-191. 
 
Brouwers PJ, Dippel DW, Vermeulen M, Lindsay KW, Hasan D, van Gijn J. Amount of 
blood on computed tomography as an independent predictor after aneurysm rupture. Stroke. 
1993 24:809-814. 
 
Busch E, Beaulieu C, de Crespigny A, Moseley ME. Diffusion MR imaging during acute 
subarachnoid hemorrhage in rats. Stroke. 1998 29:2155-2161. 
 
Conway JE, Tamargo RJ. Cocaine use is an independent risk factor for cerebral vasospasm 
after aneurysmal subarachnoid hemorrhage. Stroke. 2001 32:2338-2343. 
 
Creissard P, Rabehenoina Ch, Sevrain L, Freger P, Hattab N, Tadié M, Clavier E, Thiebot J, 
Laissy JP. Intérêt du scanner et de l’artériographie de contrôle dans l’étude des resultants de la 
Chrirugie Anévrismale: une série de 100 cas consécutifs. Neurochirurgie 1990 36:209-217. 
 
   
  25  
 
 
 
 
Crompton MR. Cerebral infarction following the rupture of cerebral berry aneurysms. Brain. 
1964 87:263-280. 
 
Dreier JP, Ebert N, Reuter U, Wolf T, Leistner S, Villringer A, Dirnagl U. Pharmacological 
transformation of spreading depression (SD) related hyperperfusion to an acute and 
longlasting hypoperfusion by NOS-inhibiton and ouabain. Soc Neurosci Abstr. 1997 23:1309. 
 
Dreier JP, Körner K, Ebert N, Görner A, Rubin I, Back T, Lindauer U, Wolf T, Villringer A, 
Einhäupl KM, Lauritzen M, Dirnagl U. Nitric oxide scavenging by hemoglobin or nitric oxide 
synthase inhibition by N-nitro-L-arginine induces cortical spreading ischemia when K+ is 
increased in the subarachnoid space. J Cereb Blood Flow Metab. 1998 18:978-990. 
 
Dreier JP, Ebert N, Priller J, Megow D, Lindauer U, Klee R, Reuter U, Imai Y, Einhaupl KM, 
Victorov I, Dirnagl U. Products of hemolysis in the subarachnoid space inducing spreading 
ischemia in the cortex and focal necrosis in rats: a model for delayed ischemic neurological 
deficits after subarachnoid hemorrhage? J Neurosurg. 2000 93:658-666. 
 
Dreier JP, Windmüller O, Petzold G, Lindauer U, Einhäupl KM, Dirnagl U. Ischemia 
triggered by red blood cell products in the subarachnoid space is inhibited by nimodipine 
administration or moderate volume expansion/hemodilution in rats. Neurosurgery. 2002a 
51:1457-1467. 
 
Dreier JP, Sakowitz OW, Harder A, Zimmer C, Dirnagl U, Valdueza JM, Unterberg AW. 
Focal laminar cortical MR-signal abnormalities after subarachnoid hemorrhage. Ann Neurol. 
2002b 52:825-829. 
 
Ecker A, Riemenschneider PA. Arteriographic demonstration of spasm of the intracranial 
arteries. With special reference to saccular arterial aneurysms. J Neurosurg. 1951 8:660-667. 
 
Edlow JA, Caplan LR. Avoiding pitfalls in the diagnosis of subarachnoid hemorrhage. N Engl 
J Med. 2000 342:29-36. 
 
Egge A, Waterloo K, Sjoholm H, Solberg T, Ingebrigtsen T, Romner B. Prophylactic 
hyperdynamic postoperative fluid therapy after aneurismal subarachnoid hemorrhage: a 
clinical, prospective, randomized, controlled study. Neurosurgery 2001 49:593-605. 
 
Espinosa F, Weir B, Overton T, Castor W, Grace M, Boisvert D. A randomized placebo-
controlled double-blind trial of nimodipine after SAH in monkeys. Part 1: Clinical and 
radiological findings. J Neurosurg 1984 60:1167-1175. 
 
Falconer MA. Surgical pathology of spontaneous intracranial haemorrhage due to aneurysms 
and arteriovenous malformations. Proc R Soc Med 1954 47:693-700. 
 
Feigin VL, Rinkel GJ, Algra A, Vermeulen M, van Gijn J: Calcium antagonists in patients 
with aneurysmal subarachnoid hemorrhage: a systematic review. Neurology 1998 50:876-883. 
 
Fisher CM, Kistler JP, Davis JM. Relation of cerebral vasospasm to subarachnoid hemorrhage 
visualized by computerized tomographic scanning. Neurosurgery. 1980 6:1-9. 
 
   
  26  
 
 
 
 
Fortuny LA, Adams CB, Briggs M. Surgical mortality in an aneurysm population: effects of 
age, blood pressure and preoperative neurological state. J Neurol Neurosurg Psychiatry. 1980 
43:879-882. 
 
George B, Zerah M, Mourier KL, Gelbert F, Reizine D. Ruptured intracranial aneurysms. The 
influence of sex and fibromuscular dysplasia upon prognosis. Acta Neurochir (Wien). 1989 
97:26-30. 
 
Gilsbach JM, Harders AG, Eggert HR, Hornyak ME. Early aneurysm surgery: a 7 year 
clinical practice report. Acta Neurochir (Wien). 1988 90:91-102. 
 
Graff-Radford NR, Torner J, Adams HP Jr, Kassell NF. Factors associated with 
hydrocephalus after subarachnoid hemorrhage. A report of the Cooperative Aneurysm Study. 
Arch Neurol. 1989 46:744-752. 
 
Haley EC Jr, Kassell NF, Apperson-Hansen C, Maile MH, Alves WM. A randomized, 
double-blind, vehicle-controlled trial of tirilazad mesylate in patients with aneurysmal 
subarachnoid hemorrhage: a cooperative study in North America. J Neurosurg. 1997 86:467-
474. 
 
Harrigan MR. Cerebral salt wasting syndrome: a review. Neurosurgery. 1996 38:152-160.  
 
Harrison MJ, Pollock S, Kendall BE, Marshall J. Effect of haematocrit on carotid stenosis and 
cerebral infarction. Lancet 1981 18:114-115. 
 
Hasan D, Vermeulen M, Wijdicks EF, Hijdra A, van Gijn J. Effect of fluid intake and 
antihypertensive treatment on cerebral ischemia after subarachnoid hemorrhage. Stroke 1989 
20:1511-1515. 
 
Haws CW, Gourley JK, Heistad DD. Effects of nimodipine on cerebral blood flow. J 
Pharmacol Exp Ther 1983 225:24-28. 
 
Hieshima GB, Higashida RT, Wapenski J, Halbach VV, Cahan L, Bentson JR. Balloon 
embolization of a large distal basilar artery aneurysm. Case report. J Neurosurg. 1986 65:413-
416. 
 
Hohlrieder M, Spiegel M, Hinterhoelzl J, Engelhardt K, Pfausler B, Kampfl A, Ulmer H, 
Waldenberger P, Mohsenipour I, Schmutzhard E. Cerebral vasospasm and ischaemic 
infarction in clipped and coiled intracranial aneurysm patients. Eur J Neurol. 2002 9:389-399. 
 
Horn J, Limburg M. Calcium antagonists for acute ischemic stroke. Cochrane Review, Issue 
4. 2001. 
 
Hubschmann OR, Kornhauser D. Cortical cellular response in acute subarachnoid 
hemorrhage. J Neurosurg. 1980 52:456-462. 
 
Inagawa T, Kamiya K, Ogasawara H, Yano T. Rebleeding of ruptured intracranial aneurysms 
in the acute stage. Surg Neurol. 1987 28:93-99. 
 
   
  27  
 
 
 
 
Inagawa T, Yamamoto M, Kamiya K, Ogasawara H. Management of elderly patients with 
aneurysmal subarachnoid hemorrhage. J Neurosurg. 1988 69:332-339. 
 
Jamme I, Petit E, Gerbi A, Maixent JM, MacKenzie ET, Nouvelot A. Changes in ouabain 
affinity of Na+, K+-ATPase during focal cerebral ischaemia in the mouse. Brain Res. 1997 
774:123-130. 
 
Karhunen PJ. Neurosurgical vascular complications associated with aneurysm clips evaluated 
by postmortem angiography. Forensic Sci Int. 1991 51:13-22. 
 
Kassell NF, Torner JC, Haley EC Jr, Jane JA, Adams HP, Kongable GL. The International 
Cooperative Study on the Timing of Aneurysm Surgery. Part 1: Overall management results. J 
Neurosurg. 1990a 73:18-36. 
 
Kassell NF, Torner JC, Jane JA, Haley EC Jr, Adams HP. The International Cooperative 
Study on the Timing of Aneurysm Surgery. Part 2: Surgical results. J Neurosurg. 1990b 
73:37-47. 
 
Kazda S, Towart R. Nimodipine: a new calcium antagonistic drug with a preferential 
cerebrovascular action. Acta Neurochir 1982 63:259-263. 
 
Kongable GL, Lanzino G, Germanson TP, Truskowski LL, Alves WM, Torner JC, Kassell 
NF. Gender-related differences in aneurysmal subarachnoid hemorrhage. J Neurosurg. 1996 
84:43-48. 
 
Kistler JP, Crowell RM, Davis KR, Heros R, Ojemann RG, Zervas T, Fisher CM. The relation 
of cerebral vasospasm to the extent and location of subarachnoid blood visualized by CT 
scan: a prospective study. Neurology. 1983 33:424-436. 
 
Kröll M, Juhler M, Lindholm J. Hyponatraemia in acute brain disease. J Intern Med. 1992 
232:291-297. 
 
Langley MS, Sorkin EM. Nimodipine. A review of its pharmacodynamic and 
pharmacokinetic properties, and therapeutic potential in cerebrovascular disease. Drugs 1989 
37:669-699. 
 
Lanzino G, Kassell NF, Germanson T, Truskowski L, Alves W. Plasma glucose levels and 
outcome after aneurysmal subarachnoid hemorrhage. J Neurosurg. 1993 79:885-891. 
 
Lanzino G, Kassell NF, Germanson TP, Kongable GL, Truskowski LL, Torner JC, Jane JA. 
Age and outcome after aneurysmal subarachnoid hemorrhage: why do older patients fare 
worse? J Neurosurg. 1996 85:410-418. 
 
Lanzino G, Kassell NF. Double-blind, randomized, vehicle-controlled study of high-dose 
tirilazad mesylate in women with aneurysmal subarachnoid hemorrhage. Part II. A 
cooperative study in North America. J Neurosurg. 1999 90:1018-1024. 
 
   
  28  
 
 
 
 
Lanzino G, Kassell NF, Dorsch NW, Pasqualin A, Brandt L, Schmiedek P, Truskowski LL, 
Alves WM. Double-blind, randomized, vehicle-controlled study of high-dose tirilazad 
mesylate in women with aneurysmal subarachnoid hemorrhage. Part I. A cooperative study in 
Europe, Australia, New Zealand, and South Africa. J Neurosurg. 1999 90:1011-1017. 
 
Lauritzen M. Pathophysiology of the migraine aura The spreading depression theory. Brain. 
1994 117:199-210. 
 
Leão AAP. Spreading depression of activity in the cerebral cortex. J Neurophysiol 1944 
7:359-390. 
 
Leão AAP, Morison RS. Propagation of spreading cortical depression. J Neurophysiol. 1945 
8:33-45. 
 
Lennihan L, Mayer SA, Fink ME, Beckford A, Paik MC, Zhang H, Wu YC, Klebanoff LM, 
Raps EC, Solomon RA. Effect of hypervolemic therapy on cerebral blood flow after 
subarachnoid hemorrhage : a randomized controlled trial. Stroke 2000 31:383-391. 
 
Lewis PJ, Weir BK, Nosko MG, Tanabe T, Grace MG. Intrathecal nimodipine therapy in a 
primate model of chronic cerebral vasospasm. Neurosurgery 1988 22:492-500. 
 
Lusic I, Ljutic D, Maskovic J, Jankovic S. Plasma and cerebrospinal fluid endogenous 
digoxin-like immunoreactivity in patients with aneurysmal subarachnoid haemorrhage. Acta 
Neurochir (Wien). 1999 141:691-697. 
 
MacDonald RL, Weir BKA. A review of hemoglobin and the pathogenesis of cerebral 
vasospasm. Stroke. 1991 22:971-982. 
 
Macdonald RL, Wallace MC, Kestle JR. Role of angiography following aneurysm surgery. J 
Neurosurg. 1993 79:826-832. 
 
Megyesi JF, Vollrath B, Cook DA, Findlay JM. In vivo animal models of cerebral vasospasm: 
a review. Neurosurgery. 2000 46:448-460; discussion 460-1. 
 
Millikan CH. Cerebral vasospasm and ruptured intracranial aneurysm. Arch Neurol. 1975 
32:433-449. 
 
Moniz E. L’Encéphalographie artérielle, son importance dans la localisation des tumeurs 
cérébrales. Rev Neurol. 1927 2:72. 
 
Müller M, Somjen GG. Na(+) and K(+) concentrations, extra- and intracellular voltages, and 
the effect of TTX in hypoxic rat hippocampal slices. J Neurophysiol. 2000 83:735-745. 
 
Nedergaard M, Hansen AJ. Characterization of cortical depolarizations evoked in focal 
cerebral ischemia. J Cereb Blood Flow Metab. 1993 13:568-574. 
 
Neil-Dwyer G, Lang DA, Doshi B, Gerber CJ, Smith PW. Delayed cerebral ischaemia: the 
pathological substrate. Acta Neurochir (Wien) 1994 131:137-145. 
 
   
  29  
 
 
 
 
Nilsson OG, Lindgren A, Stahl N, Brandt L, Saveland H. Incidence of intracerebral and 
subarachnoid haemorrhage in southern Sweden. J Neurol Neurosurg Psychiatry. 2000 69:601-
607. 
 
Nosko M, Weir B, Krueger C, Cook D, Norris S, Overton T, Boisvert D. Nimodipine and 
chronic vasospasm in monkeys: Part 1. Clinical and radiological findings. Neurosurgery 1985 
16:129-136. 
 
Nosko M, Krueger CA, Weir BK, Cook DA. Effects of nimodipine on in vitro contractility of 
cerebral arteries of dog, monkey, and man. J Neurosurg 1986 65:376-381. 
 
Öhman J, Servo A, Heiskanen O. Risks factors for cerebral infarction in good-grade patients 
after aneurysmal subarachnoid hemorrhage and surgery: a prospective study. J Neurosurg. 
1991 74:14-20. 
 
Ohta T, Kajikawa H, Yoshikawa Y, Shimizu K, Funatsu N, Yamamoto M, Toda N. Cerebral 
vasospasm and hemoglobin: clinical and experimental studies. In: Wilkins RH (ed). Cerebral 
arterial spasm. Baltimore, Williams & Wilkins, 1980, pp 166-172. 
 
Ohta O, Osaka K, Siguma M, Yamamoto M, Shimizu K, Toda N. Cerebral vasospasm 
following ruptured intracranial aneurysms, especially some contributions of potassium ion 
released from subarachnoid hematoma to delayed cerebral vasospasm. In: Bevan JA (ed). 
Vascular Neuroeffector Mechanisms. New York, Raven Press, 1983, pp 353-358. 
 
Pisani A, Calabresi P, Tozzi A, D'Angelo V, Bernardi G. L-type Ca2+ channel blockers 
attenuate electrical changes and Ca2+ rise induced by oxygen/glucose deprivation in cortical 
neurons. Stroke 1998 29:196-202. 
 
Pluta RM, Thompson BG, Dawson TM, Snyder SH, Boock RJ, Oldfield EH: Loss of nitric 
oxide synthase immunoreactivity in cerebral vasospasm. J Neurosurg. 1996 84:648-654. 
 
Pluta RM, Afshar JK, Boock RJ, Oldfield EH. Temporal changes in perivascular 
concentrations of oxyhemoglobin, deoxyhemoglobin, and methemoglobin after subarachnoid 
hemorrhage. J Neurosurg. 1998 88:557-561. 
 
Pobereskin LH. Influence of premorbid factors on survival following subarachnoid 
hemorrhage. J Neurosurg. 2001 95:555-559. 
 
Polin RS, Coenen VA, Hansen CA, Shin P, Baskaya MK, Nanda A, Kassell NF. Efficacy of 
transluminal angioplasty for the management of symptomatic cerebral vasospasm following 
aneurysmal subarachnoid hemorrhage. J Neurosurg. 2000 92:284-290. 
 
Proust F, Hannequin D, Langlois O, Freger P, Creissard P. Causes of morbidity and mortality 
after ruptured aneurysm surgery in a series of 230 patients. The importance of control 
angiography. Stroke. 1995 26:1553-1557. 
 
Qureshi AI, Suri MF, Sung GY, Straw RN, Yahia AM, Saad M, Guterman LR, Hopkins LN. 
Prognostic significance of hypernatremia and hyponatremia among patients with aneurysmal 
subarachnoid hemorrhage. Neurosurgery. 2002 50:749-755; discussion 755-6. 
   
  30  
 
 
 
 
Robertson EG. Cerebral lesions due to intracranial aneurysms. Brain 1949 72:150-185. 
 
Rosenorn J, Eskesen V, Schmidt K. Clinical features and outcome in females and males with 
ruptured intracranial saccular aneurysms. Br J Neurosurg. 1993 7:287-90. 
 
Rosenwasser RH, Delgado TE, Buchheit WA, Freed MH. Control of hypertension and 
prophylaxis against vasospasm in cases of subarachnoid hemorrhage: a preliminary report. 
Neurosurgery 1983 12:658-661. 
 
Sakaki S, Ohta S, Ohue S, Kohno K, Matsuoka K. Outcome in elderly patients with ruptured 
intracranial aneurysm. Clin Neurol Neurosurg. 1989 91:21-27. 
 
Sakr YL, Ghosn I, Vincent JL. Cardiac manifestations after subarachnoid hemorrhage: a 
systematic review of the literature. Prog Cardiovasc Dis. 2002 45:67-80. 
Scriabine A, Schuurman T, Traber J. Pharmacological basis for the use of nimodipine in 
central nervous system disorders. FASEB J 1989 3:1799-1806. 
 
Shimoda M, Takeuchi M, Tominaga J, Oda S, Kumasaka A, Tsugane R. Asymptomatic 
versus symptomatic infarcts from vasospasm in patients with subarachnoid hemorrhage: serial 
magnetic resonance imaging. Neurosurgery. 2001 49:1341-1348; discussion 1348-1350. 
 
Stoltenburg-Didinger G, Schwarz K. Brain lesions secondary to subarachnoid hemorrhage 
due to ruptured aneurysms. In: Cervós-Navarro J, Ferszt R (eds). Stroke and microcirculation. 
New York, Raven Press, 1987, pp 471-480. 
 
Toghi H, Yamanouchi H, Murakami M, Kameyama M. Importance of the hematocrit as a risk 
factor in cerebral infarction. Stroke 1978 9:369-374. 
 
Tzourio C, Kittner SJ, Bousser MG, Alperovitch A. Migraine and stroke in young women. 
Cephalalgia. 2000 20:190-199. 
 
Unterberg AW, Sakowitz OW, Sarrafzadeh AS, Benndorf G, Lanksch WR. Role of bedside 
microdialysis in the diagnosis of cerebral vasospasm following aneurysmal subarachnoid 
hemorrhage. J Neurosurg. 2001 94:740-749. 
 
Van Gijn J, Rinkel GJE. Subarachnoid haemorrhage: diagnosis, causes and management. 
Brain 2001 124:249-278. 
 
Vermeij FH, Hasan D, Bijvoet HW, Avezaat CJ. Impact of medical treatment on the outcome 
of patients after aneurismal subarachnoid hemorrhage. Stroke 1998 29:924-930. 
 
Vora YY, Suarez-Almazor M, Steinke DE, Martin ML, Findlay JM. Role of transcranial 
Doppler monitoring in the diagnosis of cerebral vasospasm after subarachnoid hemorrhage. 
Neurosurgery. 1999 44:1237-1247. 
 
Weir BK, Kongable GL, Kassell NF, Schultz JR, Truskowski LL, Sigrest A. Cigarette 
smoking as a cause of aneurysmal subarachnoid hemorrhage and risk for vasospasm: a report 
of the Cooperative Aneurysm Study. J Neurosurg. 1998 89:405-411. 
 
   
  31  
 
 
 
 
Wijdicks EF, Ropper AH, Hunnicutt EJ, Richardson GS, Nathanson JA. Atrial natriuretic 
factor and salt wasting after aneurysmal subarachnoid hemorrhage. Stroke. 1991 22:1519-
1524. 
 
Winn HR, Richardson AE, Jane JA. The long-term prognosis in untreated cerebral aneurysms: 
I. The incidence of late hemorrhage in cerebral aneurysm: a 10-year evaluation of 364 
patients. Ann Neurol. 1977 1:358-370. 
 
Wong GY, Warner DO, Schroeder DR, Offord KP, Warner MA, Maxson PM, Whisnant JP. 
Risk of surgery and anesthesia for ischemic stroke. Anesthesiology. 2000 92:425-432. 
 
Zimmermann M, Seifert V. Endothelin and subarachnoid hemorrhage: an overview. 
Neurosurgery. 1998 43:863-875; discussion 875-6. 
 
Zubkov YN, Nikiforov BM, Shustin VA. Balloon catheter technique for dilatation of 
constricted cerebral arteries after aneurysmal SAH. Acta Neurochir (Wien). 1984 70:65-79. 
   
  32  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
EIDESSTATTLICHE VERSICHERUNG 
 
gemäß Habilitationsordnung der Charité 
 
 
 
Hiermit erkläre ich, dass 
 
- keine staatsanwaltschaftlichen Ermittlungsverfahren gegen mich anhängig sind, 
 
- weder früher noch gleichzeitig ein Habilitationsverfahren durchgeführt oder 
angemeldet wurde, 
 
- die vorgelegte Habilitationsschrift ohne fremde Hilfe verfasst, die beschriebenen 
Ergebnisse selbst gewonnen wurden, sowie die verwendeten Hilfsmittel, die 
Zusammenarbeit mit anderen Wissenschaftlerinnen oder Wissenschaftlern und 
technischen Hilfskräften und die Literatur vollständig angegeben sind, 
 
- dem Bewerber die geltende Habilitationsordnung bekannt ist. 
 
 
 
 
 
 
Datum      Unterschrift 
